A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy
Recruiting · NCT06549907 · Observational (researchers observe without assigning treatment) · Lead sponsor: Peking University Cancer Hospital & Institute
View the official record on ClinicalTrials.gov →Interventions studied
MRIMulti-omics testing
What this trial is about
This study is a single-center prospective exploratory research, aiming to identify clinical characteristics and biomarkers associated with the therapeutic effects of dual PD1/PDL1 and CTLA4 blockade plus anti-angiogenic therapy and investigate MR image characteristics during treatment in patients with MSS metastatic colorectal cancer and MSI solid tumors resistant to PD-1/PD-L1 antibody monotherapy.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Pathologically confirmed MSS metastatic colorectal cancers or MSI solid tumors refractory to PD1/PDL1 antibody monotherapy
- Receiving dual blockade of PD1/PDL1 and CTLA4 in combination of anti-angiogenic treatment with or without other therapies
Exclusion criteria
- ●Having malignancies in non-gastrointestinal system that have not been cured (Lynch syndrome not included)
Where it is running
1 location listed.
- Jian Li - Beijing, Beijing Municipality, China